Generic Name and Formulations:
Midodrine HCl 2.5mg, 5mg, 10mg; scored tabs.
Various generic manufacturers
Indications for Midodrine:
Symptomatic orthostatic hypotension.
Take during the day while upright; allow at least 4 hours between last dose and bedtime. 10mg 3 times daily at 3–4 hour intervals. Renal dysfunction: initially 2.5mg 3 times daily. Discontinue if no improvement after initial therapy.
Severe heart disease. Acute renal disease. Urinary retention. Pheochromocytoma. Thyrotoxicosis. Persistent, excessive supine hypertension.
Initial supine systolic pressure >180mmHg: not recommended. Monitor supine and sitting BP. Discontinue if supine hypertension occurs. Diabetes. Renal or hepatic impairment. Pregnancy (Cat.C). Nursing mothers.
Avoid concomitant drugs that increase BP (eg, phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, droxidopa); if unavoidable, monitor BP closely. Avoid concomitant MAO inhibitors or linezolid. Potentiated by sodium-retaining steroids (eg, fludrocortisone acetate); caution in increased intraocular pressure with fludrocortisone. Antagonized by α-antagonists (eg, prazosin, terazosin, doxazosin). Levels may be affected by renally-excreted alkaline drugs (eg, metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, quinidine). Cardiac glycosides, β-blockers, CNS drugs may cause bradycardia, AV block, arrhythmias; discontinue if bradycardia occurs.
Paresthesia, piloerection, dysuria, pruritus, supine hypertension, chills, pain, rash.
Formerly known under the brand name Proamatine.
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes